Adherence to novel oral anticancer therapies in the phase I setting: The Royal Marsden experience.
Chenard-Poirier M, Ang J, Harris S, Ingles Garces A, Seeramreddi S, Sundar R, Collins D, Ameratunga M, Lopez J, De Bono J, Banerji U. Adherence to novel oral anticancer therapies in the phase I setting: The Royal Marsden experience. Journal Of Clinical Oncology 2017, 35: 2542-2542. DOI: 10.1200/jco.2017.35.15_suppl.2542.Peer-Reviewed Original ResearchPhase I trialOral anticancer therapyI trialInvestigational medicinal productsAdherence ratesAnticancer therapyAssociated with improved adherenceEarly-phase trial designsFasting requirementsRoyal Marsden HospitalAnti-emetic useAssociated with poor adherenceDrug Development UnitAssociations to adherenceIntracranial metastasesGeneral cancer populationSystemic therapyConcomitant medicationsMedian agePost-doseInterpretation of toxicityMedian timeDiary cardsUnivariate analysisAnti-emetics